History of AIHA and/or ITP was collected as complications of CLL, including status at study entry (ongoing/resolved), from 386 patients who received study treatment for this analysis (n = 195 ibrutinib; n = 191 ofatumumab). Per the study protocol, AIHA was defined by at least one marker of hemolysis (indirect bilirubin above the upper limit of normal (ULN) not due to liver disease, increased lactate dehydrogenase (above ULN) without alternative etiology, or increased absolute reticulocytes (above ULN) or bone marrow erythropoiesis in the absence of bleeding) and at least one marker of autoimmune mechanism (positive direct antiglobulin for IgG or C3d, cold agglutinins). 6 ITP was defined by platelets ⩽ 100 000 per μl and increased megakaryocytes on bone marrow exam. Patients with uncontrolled AIHA or ITP (defined as declining counts within the screening period or requirement for steroids 420 mg daily) were excluded from the RESONATE study. Other patients with AIHA/ITP including those meeting IWCLL 2008 criteria for treatment were eligible. 7 Standard supportive care medications were permitted per protocol.
Protocol-defined AIHA and ITP were reported at the discretion of the investigator at study entry based on assessments made during the screening period. Baseline hemoglobin and platelet counts for the present analysis were based on measurements from the first day of study treatment. Hemoglobin and platelet counts over time were assessed in patients with ongoing AIHA (n = 21 ibrutinib; n = 9 ofatumumab) and ongoing ITP (n = 12 ibrutinib; n = 10 ofatumumab) at study entry, respectively. Corticosteroid use for autoimmune complications and treatment-emergent adverse events (AEs) of AIHA and ITP were collected for all treated patients. Ofatumumab data were censored at initiation of crossover to ibrutinib. Ofatumumab regimen was limited to 6 months; AE reporting period for this arm was complete at publication of interim analysis. 5 Status of AIHA and ITP associated with CLL at study entry is shown in Table 1 Citation: Blood Cancer Journal (2017) 7, e524; doi:10.1038/bcj.2017.5 www.nature.com/bcj respectively, at baseline, and 13.9 g/dl (range: 11.1-15.5) and 115 × 10 9 per liter (range: 58-186 × 10 9 ), respectively, at 24 weeks. Baseline hemoglobin in patients with AIHA was similar between arms. Baseline platelet count in patients with ITP was lower with ibrutinib than ofatumumab. Median hemoglobin level and platelet counts improved early following ibrutinib initiation and were generally sustained throughout a median 18.9 months of followup. Although data were limited for the patients with ongoing AIHA in the ofatumumab arm, it appears that these patients also experienced some improvement in hemoglobin levels during the follow-up.
For all treated patients (n = 195 ibrutinib; n = 191 ofatumumab), median treatment duration (reflecting AE follow-up) was 18.3 months for patients on ibrutinib versus 5.3 months for ofatumumab. Median treatment duration for patients on ibrutinib with ongoing AIHA and ITP at study entry was 17.7 and 17.3 months, respectively. Five ibrutinib patients with ongoing AIHA were receiving concomitant corticosteroids for autoimmune cytopenias (AIC) at baseline; one discontinued corticosteroids on day 42 of therapy. One ofatumumab patient with ITP was receiving concomitant corticosteroids for autoimmune complications at baseline and during the treatment period. Corticosteroid use was initiated for AIC in four patients on ofatumumab, compared with one on ibrutinib who had prior medical history of AIHA.
The AE profile for patients with ongoing AIHA/ITP randomized to ibrutinib (Supplementary Table 1 ) was similar to the overall ibrutinib population. Among all treated patients, two developed AIHA and two developed ITP; all four were randomized to the ofatumumab arm. Of the two patients with AIHA, one was treated with prednisolone for 16 days and was ongoing at time of analysis; the other was hospitalized and treated with transfusion, prednisolone, folic acid, and eventually splenectomy. Of the two patients with ITP, one received platelets, and the ITP resolved; the other had a longer course of ITP that required intravenous immunoglobulin, steroids and platelets. No new AICs were reported as an AE in patients randomized to ibrutinib.
Treatment-emergent AIC has long been recognized as a possible complication of CLL. Initially, most of the data reporting on AIC in patients receiving ibrutinib have been described in case reports. Several cases showed activity of ibrutinib in controlling steroid-refractory AIHA in high-risk del17p CLL, 8, 9 or cessation of sequential episodes of severe AIHA/ITP and Coombs test negativity in a patient with similar prognostic features. 10 Interestingly, acute recurrence or 'flare' of AIC following ibrutinib initiation has been reported in a series of CLL patients. 11 The majority of these patients continued to receive ibrutinib with or without the addition of other therapies (most commonly steroids and IVIG) to treat the autoimmune complication, which led to resolution or control of AIC in most patients in this series. 11 To explore the effect of ibrutinib on AIC, Rogers et al.
12
retrospectively collected data on 301 patients enrolled in four sequential clinical trials. Of 22 patients receiving therapy for AIC during ibrutinib treatment, 19 were able to discontinue immunosuppressive therapy (including but not limited to corticosteroids). Furthermore, ibrutinib was associated with a low rate of treatment-emergent AIC. Letter to the Editor Data from our study in a cohort of patients at increased risk for AIC corroborate findings that ibrutinib does not precipitate recurrence of AIHA/ITP and can be administered in patients with previous history of these complications. In our analysis, ofatumumab did not lead to exacerbation or decrease in blood counts in the majority of treated patients, likely due to the fact that CD20 monoclonal antibodies themselves have long been considered as adjunct therapy for AIC. These observations are notable in contrast with the history of purine analog therapies such as fludarabine, which have been known to trigger the development of AIHA/ITP, particularly in monotherapy. Therapy-triggered AIHA has also been reported in 1-5% of CLL patients treated with fludarabine-containing combination regimens. 1 In our study, no new cases of AIHA or ITP occurred in patients on ibrutinib with a median treatment duration of 18.3 months, compared with four patients on ofatumumab with a median treatment duration of 5.3 months.
Limitations of these analyses include that history of autoimmune process was reported without serially monitoring serologic findings associated with these events, and uncontrolled AIHA or ITP was not assessed, though this population is frequently excluded in studies of CLL. 12 Further, this study did not contain patients who solely were experiencing AIC as their only manifestation of CLL, as all patients had measurable lymphadenopathy and the majority had other manifestations of active or progressive CLL. Although mechanisms of autoimmune disease in CLL are not extensively understood, a potential role for FcγR signaling has been noted in autoimmune arthritis models implicating BTK inhibition in the suppression of BCR and FcγR signaling. 13, 14 Additional evidence suggests that AIC may be mediated by polyclonal B-and T-cell responses rather than by the malignant B-cell clone. 15 Further elucidation of a putative FcR-based mechanism and other underlying mechanisms in inflammatory autoimmune disorders such as AIHA/ITP will aid in CLL treatment decision-making and contribute to our understanding of the beneficial effects of ibrutinib. 13 
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